The inflammatory skin diseases laboratory at the Icahn School of Medicine at Mount Sinai (ISMMS) made paradigm-shifting discoveries on the immunologic basis of atopic dermatitis/eczema and its different phenotypes in humans, enriching the understanding of its pathophysiology, ultimately opening the door to new therapeutics. The discoveries from the research done in the laboratory are now translating to new treatments and to clinical trials with novel therapeutic targets for atopic dermatitis. The laboratory also studies the role of inflammatory pathways and immune-barrier interactions in patients with inflammatory skin diseases, including atopic dermatitis/eczema, alopecia areata, ichthyosis vulgaris, contact hypersensitivity, and other inflammatory conditions.

Members of the laboratory have close collaborations with faculty members of the allergy group, including Hugh Sampson, Anna Nowak, and Scott Sicherer in an attempt to understand the “allergic” associations of atopic dermatitis and develop prevention strategies for the atopic march.

We are also building collaborations with Brian Brown to explore some of the human findings in mouse models of alopecia areata and other inflammatory skin diseases.

Collaborations are also being established with the immune-monitoring center at ISMMS, to be able to perform high scale phenotyping of multiple immune cells in both skin and blood of patients with inflammatory skin diseases.

Investigators with a major focus in transplant include: Michel Enamorado; Emma Guttman-Yassky, Sergio Lira